Company News-Bio-Thera Solutions, Ltd.

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

09-252020

Bio-Thera Solutions Partners with Pharmapark to Market BAT2506 in Russia and other CIS Countries

GUANGZHOU, China & MOSCOW--(BUSINESS WIRE)--Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical compan...
06-202020

NMPA Accepts Bio-Thera Solutions' Biologics License Application (BLA) for BAT1706, A Proposed Biosimilar to Avastin®

GUANGZHOU, China--(BUSINESS WIRE "BAT1706 is the company's second application for marketing approval of a Biosimilar in ...
02-032020

Bio-Thera Solutions Announces Positive Top-Line Results for BAT1706, A Proposed Biosimilar to Avastin®

GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, a commercial-stage biopharmaceutical company, today announced th...

上一页 ···25 26 27 28 29 ··· 下一页